Friday, Sept. 11, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $391.44 to $29,037,500.00.

Highlighted Stocks Traded by Insiders:

Mattersight (MATR) - FREE Research Report

Conway Kelly D, who is President & CEO at Mattersight, sold 19,120 shares at $6.60 on Sept. 11, 2015. Following this transaction, the President & CEO owned 973,202 shares meaning that the stake was reduced by 1.93% with the 19,120-share transaction.

The shares most recently traded at $6.81, up $0.21, or 3.08% since the insider transaction. Historical insider transactions for Mattersight go as follows:

  • 4-Week # shares bought: 83,641
  • 4-Week # shares sold: 5,790
  • 12-Week # shares bought: 83,641
  • 12-Week # shares sold: 5,790
  • 24-Week # shares bought: 83,641
  • 24-Week # shares sold: 38,946

The average volume for Mattersight has been 52,000 shares per day over the past 30 days. Mattersight has a market cap of $170.3 million and is part of the technology sector and computer software & services industry. Shares are up 6.24% year-to-date as of the close of trading on Friday.

Mattersight Corporation provides enterprise analytics services with a focus on customer and employee interactions and behaviors in the United States and the United Kingdom. Currently, there are 2 analysts who rate Mattersight a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MATR - FREE

TheStreet Quant Ratings

rates Mattersight as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

Mattersight Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Violin Memory (VMEM) - FREE Research Report

Nottenburg Richard N, who is Director at Violin Memory, bought 25,000 shares at $1.48 on Sept. 11, 2015. Following this transaction, the Director owned 150,000 shares meaning that the stake was boosted by 20% with the 25,000-share transaction.

Mahadevan Vivekanand, who is Director at Violin Memory, bought 3,000 shares at $1.52 on Sept. 11, 2015. Following this transaction, the Director owned 4,700 shares meaning that the stake was boosted by 176.47% with the 3,000-share transaction.

The shares most recently traded at $1.84, up $0.32, or 17.21% since the insider transaction. Historical insider transactions for Violin Memory go as follows:

  • 4-Week # shares bought: 151,000
  • 12-Week # shares bought: 151,000
  • 24-Week # shares bought: 159,928

TheStreet Recommends

The average volume for Violin Memory has been 1.3 million shares per day over the past 30 days. Violin Memory has a market cap of $148.5 million and is part of the technology sector and computer hardware industry. Shares are down 62.84% year-to-date as of the close of trading on Friday.

Violin Memory, Inc. develops and supplies memory-based storage systems to bring storage performance in line with high-speed applications, servers, and networks worldwide. Currently, there is 1 analyst who rates Violin Memory a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VMEM - FREE

TheStreet Quant Ratings

rates Violin Memory as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally disappointing historical performance in the stock itself. Get the full

Violin Memory Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DexCom (DXCM) - FREE Research Report

Lord Jonathan T Md, who is Director at DexCom, sold 10,000 shares at $90.96 on Sept. 11, 2015. Following this transaction, the Director owned 131,582 shares meaning that the stake was reduced by 7.06% with the 10,000-share transaction.

The shares most recently traded at $95.50, up $4.54, or 4.75% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 38,496
  • 12-Week # shares sold: 100,256
  • 24-Week # shares sold: 135,067

The average volume for DexCom has been 1.1 million shares per day over the past 30 days. DexCom has a market cap of $7.7 billion and is part of the health care sector and health services industry. Shares are up 76.95% year-to-date as of the close of trading on Friday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently, there are 11 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings

rates DexCom as a

sell

. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full

DexCom Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.